Insulet (Insulet) 5-Year EBITDA Growth Rate

: 31.90% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Insulet's EBITDA per Share for the three months ended in Dec. 2023 was $1.58.

During the past 12 months, Insulet's average EBITDA Per Share Growth Rate was 181.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 38.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 31.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Insulet was 262.50% per year. The lowest was -15.90% per year. And the median was 34.85% per year.

Competitive Comparison

For the Medical Devices subindustry, Insulet's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insulet 5-Year EBITDA Growth Rate Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Insulet's 5-Year EBITDA Growth Rate falls into.

Insulet 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Insulet (NAS:PODD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Insulet 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Insulet's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet (Insulet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PODD:Mexico GOV:Germany GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Executives

Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic	officer: CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh	officer: SVP, Global Operations	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead	director	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan	officer: EVP, CFO	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field	officer: SVP & Chief Technology Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea	officer: SVP, Chief HR Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue	director	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin	officer: SVP, Reg, Quality & Compliance	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche	officer: SVP, Global Manufacturing	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen	officer: SVP and CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears	officer: SVP, Quality and Regulatory	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine	director	C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford	director	C/O HOLOGIC, INC., BEDFORD MA 01730